Northwest Biotherapeutics, Inc. (NWBO)
USD 0.21
(-1.87%)
USD 0.21
(-1.87%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 20.31 Million USD | 96.04% |
| 2022 | 10.36 Million USD | -65.9% |
| 2021 | 30.38 Million USD | 126.34% |
| 2020 | 13.42 Million USD | 16.7% |
| 2019 | 11.5 Million USD | 479.15% |
| 2018 | 1.98 Million USD | -76.68% |
| 2017 | 8.51 Million USD | 183.9% |
| 2016 | 3 Million USD | -70.26% |
| 2015 | 10.08 Million USD | -58.82% |
| 2014 | 24.49 Million USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 1.88 Million USD | 15.25% |
| 2011 | 1.63 Million USD | -11.92% |
| 2010 | 1.85 Million USD | 36.42% |
| 2009 | 1.35 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 3000.00 USD | -75.0% |
| 2004 | 12 Thousand USD | -75.51% |
| 2003 | 49 Thousand USD | -50.0% |
| 2002 | 98 Thousand USD | -20.46% |
| 2001 | 123.21 Thousand USD | -84.62% |
| 2000 | 801.34 Thousand USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 10.21 Million USD | -49.71% |
| 2024 Q2 | 20.43 Million USD | 100.04% |
| 2023 Q1 | 20.38 Million USD | 96.79% |
| 2023 Q3 | 15.17 Million USD | -24.56% |
| 2023 Q2 | 20.11 Million USD | -1.36% |
| 2023 Q4 | 20.31 Million USD | 33.88% |
| 2023 FY | 20.31 Million USD | 96.04% |
| 2022 Q4 | 10.36 Million USD | 2.85% |
| 2022 Q3 | 10.07 Million USD | -52.09% |
| 2022 Q1 | 21.17 Million USD | -30.32% |
| 2022 FY | 10.36 Million USD | -65.9% |
| 2022 Q2 | 21.02 Million USD | -0.67% |
| 2021 FY | 30.38 Million USD | 126.34% |
| 2021 Q1 | 22.25 Million USD | 65.77% |
| 2021 Q3 | 17.63 Million USD | -1.5% |
| 2021 Q2 | 17.9 Million USD | -19.55% |
| 2021 Q4 | 30.38 Million USD | 72.3% |
| 2020 Q4 | 13.42 Million USD | 0.43% |
| 2020 FY | 13.42 Million USD | 16.7% |
| 2020 Q3 | 13.36 Million USD | 74.64% |
| 2020 Q2 | 7.65 Million USD | 69.46% |
| 2020 Q1 | 4.51 Million USD | -60.74% |
| 2019 Q2 | 12.24 Million USD | 39.97% |
| 2019 Q1 | 8.75 Million USD | 340.58% |
| 2019 FY | 11.5 Million USD | 479.15% |
| 2019 Q4 | 11.5 Million USD | 2.18% |
| 2019 Q3 | 11.25 Million USD | -8.08% |
| 2018 Q4 | 1.98 Million USD | -87.74% |
| 2018 FY | 1.98 Million USD | -76.68% |
| 2018 Q1 | 9.11 Million USD | 7.03% |
| 2018 Q2 | 13.72 Million USD | 50.5% |
| 2018 Q3 | 16.19 Million USD | 18.05% |
| 2017 Q2 | 9.83 Million USD | 222.81% |
| 2017 Q1 | 3.04 Million USD | 1.57% |
| 2017 FY | 8.51 Million USD | 183.9% |
| 2017 Q4 | 8.51 Million USD | -25.6% |
| 2017 Q3 | 11.44 Million USD | 16.38% |
| 2016 Q2 | 10.36 Million USD | 1.37% |
| 2016 Q1 | 10.22 Million USD | 1.39% |
| 2016 Q3 | - USD | -100.0% |
| 2016 FY | 3 Million USD | -70.26% |
| 2016 Q4 | 3 Million USD | 0.0% |
| 2015 Q1 | 28.99 Million USD | 18.4% |
| 2015 Q3 | 20.45 Million USD | -8.13% |
| 2015 Q2 | 22.26 Million USD | -23.21% |
| 2015 Q4 | 10.08 Million USD | -50.7% |
| 2015 FY | 10.08 Million USD | -58.82% |
| 2014 Q4 | 24.49 Million USD | 55.82% |
| 2014 Q3 | 15.71 Million USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 24.49 Million USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | 1.31 Million USD | -30.07% |
| 2013 Q2 | - USD | -100.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 Q4 | 1.88 Million USD | -20.89% |
| 2012 Q2 | 1.34 Million USD | 22.54% |
| 2012 FY | 1.88 Million USD | 15.25% |
| 2012 Q1 | 1.09 Million USD | -32.88% |
| 2012 Q3 | 2.37 Million USD | 77.14% |
| 2011 Q1 | 1.62 Million USD | -12.51% |
| 2011 FY | 1.63 Million USD | -11.92% |
| 2011 Q4 | 1.63 Million USD | -13.96% |
| 2011 Q3 | 1.89 Million USD | 75.42% |
| 2011 Q2 | 1.08 Million USD | -33.29% |
| 2010 Q1 | 1.27 Million USD | -6.25% |
| 2010 Q2 | 1.64 Million USD | 28.96% |
| 2010 Q3 | 3.42 Million USD | 108.28% |
| 2010 Q4 | 1.85 Million USD | -45.82% |
| 2010 FY | 1.85 Million USD | 36.42% |
| 2009 Q4 | 1.35 Million USD | 58.58% |
| 2009 FY | 1.35 Million USD | 0.0% |
| 2009 Q2 | 696 Thousand USD | 1.31% |
| 2009 Q3 | 857 Thousand USD | 23.13% |
| 2009 Q1 | 687 Thousand USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | -100.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q1 | 1000.00 USD | -66.67% |
| 2005 FY | 3000.00 USD | -75.0% |
| 2005 Q1 | 7000.00 USD | -41.67% |
| 2005 Q4 | 3000.00 USD | -25.0% |
| 2005 Q2 | 5000.00 USD | -28.57% |
| 2005 Q3 | 4000.00 USD | -20.0% |
| 2004 FY | 12 Thousand USD | -75.51% |
| 2004 Q4 | 12 Thousand USD | -33.33% |
| 2004 Q3 | 18 Thousand USD | -35.71% |
| 2004 Q1 | 38 Thousand USD | -22.45% |
| 2004 Q2 | 28 Thousand USD | -26.32% |
| 2003 Q4 | 49 Thousand USD | -16.95% |
| 2003 Q2 | 69 Thousand USD | -17.86% |
| 2003 Q3 | 59 Thousand USD | -14.49% |
| 2003 Q1 | 84 Thousand USD | -14.29% |
| 2003 FY | 49 Thousand USD | -50.0% |
| 2002 Q1 | 107.29 Thousand USD | -12.92% |
| 2002 Q2 | 138.64 Thousand USD | 29.22% |
| 2002 Q3 | 115 Thousand USD | -17.05% |
| 2002 Q4 | 98 Thousand USD | -14.78% |
| 2002 FY | 98 Thousand USD | -20.46% |
| 2001 Q4 | 123.21 Thousand USD | -56.0% |
| 2001 FY | 123.21 Thousand USD | -84.62% |
| 2001 Q1 | 778.61 Million USD | 0.0% |
| 2001 Q3 | 280 Thousand USD | -3.45% |
| 2001 Q2 | 290 Thousand USD | -99.96% |
| 2000 FY | 801.34 Thousand USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -253800.0% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -1057.063% |
| Qrons Inc. | 80 Thousand USD | -25290.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -11762.407% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 2.855% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -34537.291% |
| Mesoblast Limited | 100.29 Million USD | 79.748% |
| Marizyme, Inc. | 667.12 Thousand USD | -2944.689% |
| Genus plc | 228.2 Million USD | 91.099% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 87.772% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -368405.08% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -819.095% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -1347.823% |
| IMV Inc. | 27.39 Million USD | 25.865% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -274.313% |
| MultiCell Technologies, Inc. | 36.43 USD | -55756144.853% |
| ONE Bio Corp. | 592.19 Thousand USD | -3329.934% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 63.476% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -812.489% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1553.586% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -3562.525% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -80187.758% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -969.915% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -6208.075% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.819% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -13441.333% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -12269.903% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -32.291% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -455734.829% |
| Genscript Biotech Corporation | 287.12 Million USD | 92.926% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -15982.089% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -8758.612% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -8743.185% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -145.789% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -7546.583% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -1908922.556% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -13476.27% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -13476.27% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -14305.674% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -159.746% |
| SYBLEU INC | 300 Thousand USD | -6670.667% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -5403.876% |
| International Stem Cell Corporation | 445 Thousand USD | -4464.494% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -149.227% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -4344.639% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -1649.526% |
| PureTech Health plc | 18.25 Million USD | -11.299% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -13441.333% |
| IXICO plc | 275 Thousand USD | -7286.182% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -71.569% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 22.794% |
| CSL Limited | 11.23 Billion USD | 99.819% |
| Cellectis S.A. | 36.21 Million USD | 43.907% |